CheckMate 057 trial in non-squamous and the CheckMate 017 trial in squamous cell NSCLC of nivolumab versus docetaxel

SURESH RAMALINGAM, MD of the Winship Cancer Institute of Emory University talks about the CheckMate 057 trial in non-squamous and the CheckMate 017 trial in squamous cell NSCLC of nivolumab versus docetaxel